GAMT facilitates tumor progression via inhibiting p53 in clear cell renal cell carcinoma
This study reveals that GAMT has pro-oncogenic abilities in promoting ccRCC development and progression. GAMT exerted its non-enzymatic functions possibly by regulating the expression of p53. Fisetin, the novel GAMT inhibitor identified herein, may serve as a new antitumor drug for ccRCC treatment.
Authors
- Kan Liu (ORCID: https://orcid.org/0000-0001-5633-0023)
- Tianwei Cai
- Shuo Tian (ORCID: https://orcid.org/0009-0004-6502-4123)
- Xinran Chen (ORCID: https://orcid.org/0000-0001-7903-362X)
- Lequan Wen (ORCID: https://orcid.org/0000-0002-9119-2022)
- Xin Ma (ORCID: https://orcid.org/0000-0002-7316-1468)
- Yaohui Wang (ORCID: https://orcid.org/0000-0003-0153-4277)
- Bin Zheng (ORCID: https://orcid.org/0000-0001-5271-7087)
- Tongyu Jia
- J. Feng (ORCID: https://orcid.org/0000-0003-2805-6818)
- Xiubin Li (ORCID: https://orcid.org/0000-0002-3060-1902)
- Qing Ouyang
Institutions
- Chinese PLA General Hospital (CN)
Publication Details
- Journal
- Biology Direct
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1186/s13062-025-00641-y
- Citations
- 2
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 1.87
Funders
- National Natural Science Foundation of China
- General Hospital of People’s Liberation Army